论文部分内容阅读
在持续数年的医药业整合兼并潮中,“黑马”东盛以赌徒式手法构建起强势平台,却也同时放大了危险性借国药飞渡从2003年3月份开始,历时5个月, 东盛集团董事长郭家学与中国医药集团(简称“国药集团”)高层接触频密,2003 年8月国药集团下属子公司“中国医药工业公司”与西安东盛集团组建合资公司“中国医药工业有限公司”,后者持股比例49%,而为此支付的现金高达4.95 亿人民币。在东盛十年资本运作史上金额最大的这笔投资投出不久,东盛资金链全面吃紧。在接受《中国企业家》采
In the pharmaceutical mergers and acquisitions that lasted for several years, the “dark horse” Tung Shing built a strong platform by the gambler style, but at the same time magnified the danger. Borrowed from the national drug Fei Du from March 2003, which took 5 months, Chairman of Dongsheng Group Guo Jiaxue and China National Pharmaceutical Group (“Sinopharm Group”) high-level contacts in August 2003 Sinopharm Group subsidiary “China Pharmaceutical Industry Corporation” and Xi’an Dongsheng Group set up a joint venture, “China Pharmaceutical Industry Co., Ltd. ”, The latter holding 49% of the shares, while the cash paid for this up to 495 million yuan. Dongsheng capital operation in the history of the largest amount of investment in the history of this investment soon, Tung Shing capital chain overall tight. Accepting “Chinese entrepreneurs” mining